



UNITED STATES PATENT AND TRADEMARK OFFICE

M

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/979,509 | 03/05/2002 | Masakazu Kawasaki | 2001-1749A | 5928 |

513 7590 09/22/2004

WENDEROTH, LIND & PONACK, L.L.P.
2033 K STREET N. W.
SUITE 800
WASHINGTON, DC 20006-1021

EXAMINER

SPIVACK, PHYLLIS G

ART UNIT PAPER NUMBER

1614

DATE MAILED: 09/22/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**UNITED STATES DEPARTMENT OF COMMERCE****U.S. Patent and Trademark Office**

Address : COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

| | | | |
|---------------------------------|-------------|---|---------------------|
| APPLICATION NO./ CONTROL NO. | FILING DATE | FIRST NAMED INVENTOR / PATENT IN REEXAMINATION | ATTORNEY DOCKET NO. |
|---------------------------------|-------------|---|---------------------|

| |
|----------|
| EXAMINER |
|----------|

| | |
|----------|-------|
| ART UNIT | PAPER |
|----------|-------|

091904

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner for Patents

The Amendment filed on April 1, 2004 is non-responsive to the prior Office Action because Applicants had elected Group I, drawn to compositions comprising a MAG expression promoter and methods for prophylaxis and/or therapy thereof. The originally presented methods were directed to prophylaxis and/or therapy of a disease caused by hypomyelination or a disease presenting dysmyelination or demyelination. This invention had been constructively elected by original presentation for prosecution on the merits. With the present Amendment the claims are no longer directed to composition claims or the originally presented methods of use. The amended subject matter is directed to methods of promoting expression of MAG and methods for promoting a myelination of axon. These newly presented methods are independent and distinct from the invention originally claimed. Since Applicants' response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, Applicants are required to complete the response within a TIME LIMIT of ONE MONTH from the date of this letter.

Any inquiry concerning this communication should be directed to Phyllis Spivack at telephone number 571-272-0585.

September 19, 2004

Phyllis Spivack
1614**PHYLLIS SPIVACK
PRIMARY EXAMINER**